title: Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization.
abstract: Studies showing psychostimulant-like effects of exogenous neurotensin (NT) infused into the ventral tegmental area (VTA) prompted us to examine the role in the VTA of the endogenous NT in behavioral sensitization to amphetamine. Rats were sensitized to amphetamine by means of a subcutaneous amphetamine (1 mg/kg) injection, and the same dose was injected 7 days later to evaluate the expression of sensitization. The highly selective NT-receptor antagonist SR 142948A was injected into the VTA prior to the first and/or second amphetamine administration. SR 142948A (5 pmol/side) given before the first amphetamine exposure prevented the induction of behavioral sensitization, but did not alter the acute response to amphetamine. SR 142948A given with the second amphetamine administration did not affect the expression of behavioral sensitization. In contrast to administration into the VTA, intraperitoneal administration of SR 142948A (0.03, 0.1, or 0.3 mg/kg) had no detectable effect on the induction of amphetamine sensitization. These results suggest that activation of VTA NT receptors by endogenous NT may contribute to the neuroadaptations underlying behavioral sensitization to amphetamine.
authors.affiliation: INSERM, U512, Lyon, France.
authors.forename: Fany
authors.initials: F
authors.lastname: Panayi
authors.forename: Joyce
authors.initials: J
authors.lastname: Colussi-Mas
authors.forename: Laura
authors.initials: L
authors.lastname: Lambás-Señas
authors.forename: Bernard
authors.initials: B
authors.lastname: Renaud
authors.forename: Hélène
authors.initials: H
authors.lastname: Scarna
authors.forename: Anne
authors.initials: A
authors.lastname: Bérod
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009496:Neurotensin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018028:Receptors, Neurotensin / Q000037:antagonists & inhibitors; D017557:Ventral Tegmental Area / Q000378:metabolism / Q000502:physiology*
chemical_list: D000697:Central Nervous System Stimulants; D007093:Imidazoles; D018028:Receptors, Neurotensin; C104418:SR 142948A; D009496:Neurotensin; D000661:Amphetamine; D000218:Adamantane